| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9198871 | ABBVIE | Delayed release pancreatin compositions |
Feb, 2030
(5 years from now) | |
Creon is owned by Abbvie.
Creon contains Pancrelipase (Amylase;Lipase;Protease).
Creon has a total of 1 drug patent out of which 0 drug patents have expired.
Creon was authorised for market use on 30 April, 2009.
Creon is available in capsule, delayed release;oral dosage forms.
Creon can be used as treatment of exocrine pancreatic insufficiency.
Drug patent challenges can be filed against Creon from 30 April, 2013.
The generics of Creon are possible to be released after 07 February, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 30, 2014 |
| M(M-93) | Jul 29, 2019 |
| New Indication(I-625) | Apr 30, 2013 |
Drugs and Companies using PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) ingredient
NCE-1 date: 30 April, 2013
Market Authorisation Date: 30 April, 2009
Treatment: Treatment of exocrine pancreatic insufficiency
Dosage: CAPSULE, DELAYED RELEASE;ORAL
CREON family patents
